Who owns Arcus Biosciences, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RCUS from SEC Form 13F filings across 230 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 230 institutions disclosed 122.6M shares of Arcus Biosciences, Inc. worth $3.78B — about 97.2% of shares outstanding; the largest disclosed holder is GILEAD SCIENCES, INC.. Source: SEC Form 13F filings, parsed by EvidInvest.
230
13F holders
$3.78B
value, 2026 filers
97.2%
of shares outstanding (122.6M sh)
47
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RCUS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 31.4M | $968.8M | 58.8% | 24.9% | 0.0% |
| 2 | BlackRock, Inc. | 16.4M | $506.1M | 0.0% | 13% | +7.8% |
| 3 | STATE STREET CORP | 6.0M | $185.9M | 0.0% | 4.8% | +11.4% |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 5.9M | $181.8M | 0.0% | 4.7% | -3.2% |
| 5 | MONTANOVA CAPITAL, LLC | 4.8M | $147.3M | 2.7% | 3.8% | -5.1% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5M | $138.0M | 0.0% | 3.5% | +4.8% |
| 7 | FMR LLC | 4.0M | $124.9M | 0.0% | 3.2% | +247.5% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $119.9M | 0.0% | 3.1% | +0.8% |
| 9 | CITADEL ADVISORS LLC | 3.1M | $96.7M | 0.0% | 2.5% | +135.7% |
| 10 | Woodline Partners LP | 3.0M | $92.7M | 0.3% | 2.4% | -20.4% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2.4M | $75.5M | 0.0% | 1.9% | +8.7% |
| 12 | Siren, L.L.C. | 2.4M | $74.6M | 1.5% | 1.9% | -19.5% |
| 13 | Fisher Asset Management, LLC | 2.1M | $66.0M | 0.0% | 1.7% | -2.3% |
| 14 | MARSHALL WACE, LLP | 1.9M | $60.0M | 0.0% | 1.5% | -48.3% |
| 15 | SAMLYN CAPITAL, LLC | 1.5M | $47.7M | 0.8% | 1.2% | -18.9% |
| 16 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $44.2M | 0.0% | 1.1% | +0.6% |
| 17 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.4M | $43.8M | 0.0% | 1.1% | -14.2% |
| 18 | GOLDMAN SACHS GROUP INC | 1.4M | $42.8M | 0.0% | 1.1% | +38.8% |
| 19 | Soleus Capital Management, L.P. | 1.2M | $36.0M | 1.2% | 0.9% | +158.6% |
| 20 | Sofinnova Investments, Inc. | 945,690 | $29.2M | 1.5% | 0.7% | +2.4% |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 941,756 | $29.0M | 0.0% | 0.7% | +4.2% |
| 22 | NORTHERN TRUST CORP | 932,523 | $28.7M | 0.0% | 0.7% | +11.0% |
| 23 | Parkman Healthcare Partners LLC | 919,266 | $28.3M | 2.9% | 0.7% | -23.9% |
| 24 | Invesco Ltd. | 845,233 | $26.1M | 0.0% | 0.7% | +3.0% |
| 25 | BAKER BROS. ADVISORS LP | 844,816 | $26.0M | 0.1% | 0.7% | +103.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.